Base de datos : IBECS
Búsqueda : "1699-048X" [ISSN]
Referencias encontradas : 2057 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 206 va a la página                         

  1 / 2057 IBECS  
              next record last record
selecciona
para imprimir
Id: 173771
Autor: Fuentes-Raspall, R; Solans, M; Auñon-Sanz, C; Saez, M; Marcos-Gragera, R.
Título: Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994û2013)
Fuente: Clin. transl. oncol. (Print);20(12):1628-1630, dic. 2018. tab.
Idioma: en.
doi: 10.1007/s12094-018-1890-8.
Resumen: No disponible
Descriptores: linfoma/epidemiología
neoplasias del sistema nervioso central/epidemiología
neoplasias cerebrales/epidemiología
-tasa de supervivencia
España/epidemiología
neoplasias cerebrales/patología
Límites: humanos
Responsable: BNCS


  2 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173770
Autor: Castel, V; Cañete, A; Calabria, I; Cervera, J; Dolz, S; Escobar, P; Font de Mora, J; Gargallo, P; Llavador, G; Pedrola, L; Yañez, Y; Zuñiga, A.
Título: Letter to the Editor: In the last CTO issue members of SEHOP SEAP and SEFH headed by Pilar Garrido
Fuente: Clin. transl. oncol. (Print);20(12):1626-1627, dic. 2018.
Idioma: en.
doi: 10.1007/s12094-018-1889-1.
Resumen: No disponible
Descriptores: oncología médica/tendencias
medicina de precisión/tendencias
pediatría/tendencias
-estrategias nacionales
sociedades médicas
Límites: humanos
niño
Tipo de Publicación: carta
comentario
Responsable: BNCS


  3 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173769
Autor: Rubió-Casadevall, J; Puig-Vives, M; Puigdemont, M; Vilardell, L; Carbó-Bagué, A; Marcos-Gragera, R; Vilar-Coromina, N.
Título: Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994û2013: a population-based study
Fuente: Clin. transl. oncol. (Print);20(12):1617-1625, dic. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1900-x.
Resumen: Introduction: We conducted a population-based study on the Girona Cancer Registry (Spain) for the period 1994û2013 to determine patterns of change in the incidence of melanoma, which is increasing in many countries, and patient survival in our geographical area. Materials and methods: Using the standard registration rules for cancer registries, we calculated crude and standardized incidence rates as well as their trends. We also analysed the observed survival, 1-year conditioned survival and relative survival at 3, 5 and 10 years. Results: Our crude incidence rate was 9.13 cases/100,000 inhabitants for invasive and 2.59 for ôin situö melanomas. A statistically significant increase in incidence was found for melanomas of less than 1 mm in Breslow index and in males. 10-year observed and relative survival rates were 64.1 and 83.1%, respectively. Conclusions: We found an increasing trend in the incidence of low-risk melanoma and a survival rate similar to that reported elsewhere in Europe

No disponible
Descriptores: melanoma/epidemiología
neoplasias cutáneas/epidemiología
-tasa de supervivencia
España/epidemiología
melanoma/patología
neoplasias cutáneas/patología
Límites: humanos
Responsable: BNCS


  4 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173768
Autor: Wulff, E.
Título: Spanish National Oncological Research Center (CNIO): a bibliometric portrait
Fuente: Clin. transl. oncol. (Print);20(12):1612-1616, dic. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1897-1.
Resumen: Introduction: Madrid's CNIO (Spanish National Oncological Research Center) ranks among the three first institutions in the world, specifically dedicated to cancer research. CNIO research mainly focuses on three aspects: use of stem cells to fix problematic cancer damage, searches for genes that cause cancer disease, and use of drug design to manage oncological disorders. Objectives: The main goal of this study is to determine the effectiveness of the 'translation' of basic discoveries generated at this cancer research center, into new interventions aimed at preventing and treating various types of cancer, with bibliometric criteria. Methods: A corpus of published articles and citations received by CNIO between 1998 and 2016 has been retrieved from the Web of Science (WoS) database. Bibliometric indicators considered here are: citation practices, use of journals on the basis of their impact factors, scientific literature citing CNIO publications, and international connectedness of CNIO researchers. Results: A total of 3510 articles were published by CNIO between 1998 and 2016, 23% of which in journals with impact factors between 10 and 15 and above 15. Along the same period, the institution received 135,769 citations published in more than 5800 journals, where the most important citing journals were the Plos One with 3.6% of all the citing articles, Oncotarget with 1.8%, and Scientific Reports with 1.2%. The highest number of citations was 18,005 in 2007; in terms of average citation rate, the first ranked CNIO research program was in the area of experimental therapeutics (77.79%), followed by molecular oncology (68.1%). This position was provided by the active growth in citation to the articles whose themes are related to the problems of the consequences of the design of preclinical drug candidates and the study of oncological disorders. Conclusions: From this study on a number of bibliometric characteristics of the Spanish National Oncological Research Center (CNIO), we conclude that the publication activity (since 2006 its scientific production has increased in about 83%), the number of high-quality journals used per year, the high influence, and impact of the journals and organizations citing the institution, consolidate its image as a top-notch oncological research center

No disponible
Descriptores: investigación médica traslacional/estadística & datos numéricos
oncología médica/tendencias
investigación biomédica/estadística & datos numéricos
-sociedades científicas/estadística & datos numéricos
informe de investigación
indicadores de publicaciones científicas
Publicaciones/estadística & datos numéricos
indicadores bibliométricos
Límites: humanos
Responsable: BNCS


  5 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173767
Autor: Muñoz-Sánchez, MM; Calderon, C; Jimenez-Fonseca, P; Soriano-Rodríguez, MC; Jara, C; García-García, T; Beato, C; Rogado, J; Castelo, B; Hernández, R; Mangas-Izquierdo, M; Carmona-Bayonas, A.
Título: Prospective analysis of psychological differences between adult and elderly cancer patients during postoperative adjuvant chemotherapy
Fuente: Clin. transl. oncol. (Print);20(12):1604-1611, dic. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1901-9.
Resumen: Purpose: Despite the burgeoning geriatric population with cancer and the importance of understanding how age may be related to mental adjustment and quality of life so far, differences in coping strategies and psychological harm between the elderly and adults are hardly being taken into account to modify the approach to this population. The aim of this prospective study is to describe the differences in psychological characteristics between older and adult cancer patients and examine dissimilarities in their psychological evolution during adjuvant chemotherapy. Methods: Adults (18û69 years old) and older patients (≥ 70) with newly diagnosed non-metastatic resected cancer admitted to receive adjuvant chemotherapy were recruited. Patients completed the following questionnaires: mini-mental adjustment to cancer, brief symptom inventory, shared decision-making questionnaireûpatient's version, multidimensional scale of perceived social support, EORTC quality-of-life instrument, life orientation test-revised, and satisfaction with life scale. Results: 500 cancer patients (394 adults and 106 older) were evaluated. The impact of the diagnosis was less negative among older patients, with no differences in coping strategies, quality of life, or search for support. Regarding psychological changes from the beginning to the end of the adjuvant treatment, both age groups reported more somatic symptoms, increased psychological difficulty, reduced coping strategies, and a significant decrease in quality of life at the end of postoperative chemotherapy. Conclusion: Although there were clear psychological differences between adults and senior cancer patients, their evolution during adjuvant chemotherapy was similar, with deterioration in quality of life and coping. This negative psychological impact of adjuvant chemotherapy should be taken into account when considering interventions

No disponible
Descriptores: adaptación psicológica
neoplasias/psicología
quimioterapia adyuvante/psicología
-Distribución por Edad
apoyo social
calidad de vida/psicología
perfil del impacto de la enfermedad
toma de decisión
período posoperatorio
Límites: humanos
adulto
anciano
Responsable: BNCS


  6 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173766
Autor: Singh, MK; Pushker, N; Meel, R; Chodsol, K; Sen, S; Bakhshi, S; Singh, L; Kashyap, S.
Título: Does NEMO/IKKgamma protein have a role in determining prognostic significance in uveal melanoma?
Fuente: Clin. transl. oncol. (Print);20(12):1592-1603, dic. 2018. ilus, tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1895-3.
Resumen: Purpose: Uveal melanoma, although a rare form of cancer, is the most common primary malignancy of the eye in adults. Nuclear factor-kapaB (NF-kapaB) is a transcription factor that transactivates genes involved in the regulation of cell growth, apoptosis, angiogenesis, and metastasis, but the molecular mechanisms that negatively regulate NF-kapaB activation are not fully understood. NF-kapaB can also be activated by DNA damage pathway through NEMO protein. Therefore, the objective of this study is to elucidate the role of NEMO/IKKgamma protein in uveal melanoma patients. Methods: Seventy-five formalin-fixed paraffin-embedded prospective tissues of uveal melanoma were included in the present study. These cases were reviewed and investigated for the expression of NEMO/IKKgamma protein by immunohistochemistry and validated by western blotting along with the qRT-PCR for mRNA expression. Expression levels were correlated with the clinicopathological parameters and patients' outcome. Results: Immunohistochemistry showed cytoplasmic expression of NEMO/IKKgamma expression in only 22 out of 75 (29.33%) cases. This result was confirmed by western blotting, and correlated well with the immunohistochemical expression of NEMO/IKKgamma protein (48 kDa). In addition, downregulation of this gene was found in 87.93% of the cases when compared with the normal tissues. On statistical analysis, loss of NEMO/IKKgamma protein was correlated with neovascularization, high mitotic count, and presence of vascular loop (p < 0.05). There was less overall survival rate with low expression of NEMO/IKKgamma protein in patients with uveal melanoma. Conclusion: This was the first study suggesting the relevant role of NEMO/IKKgamma protein, and highlights the prognostic significance with outcome in uveal melanoma patients. This protein might be used as a screening biomarker in these patients after large-scale validation and translational studies

No disponible
Descriptores: neoplasias de la úvea/genética
melanoma/genética
NF-kappa B/genética
activador del receptor del factor nuclear kappa B/genética
-neoplasias de la úvea/patología
melanoma/patología
marcadores genéticos/genética
inmunohistoquímica/métodos
investigación médica traslacional
Límites: humanos
Responsable: BNCS


  7 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173765
Autor: Arena, S; Salati, M; Sorgentoni, G; Barbisan, F; Orciani, M.
Título: Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer
Fuente: Clin. transl. oncol. (Print);20(12):1582-1591, dic. 2018. ilus, graf.
Idioma: en.
doi: 10.1007/s12094-018-1894-4.
Resumen: Purpose: The goal of this study was to understand if mesenchymal stem cells isolated from lung tumor tissue (T-MSCs) may differentiate into cancer associated fibroblasts (CAFs), that promote neoplastic progression, angiogenesis and metastasis in the epithelial solid tumors, mimicking the tumor microenvironmental influence. Methods: MSCs were been obtained from healthy (Control, C-MSCs) and tumor (T-MSCs) tissue of one patient who underwent a lobectomy for a lung adenocarcinoma pT1bN0. Isolated cells were characterized for the presence of molecular markers (identified by routine diagnostic characterization in differentiated tumoral cells), stemness properties, and CAF-related markers expression. Subsequently, cells were co-cultured with a lung adenocarcinoma cell line (A549 cells) to evaluate the effects on proliferation, oncogene expression and IL6 secretion. Results: C- and T-MSCs did not present EGFR mutations unlike tumor tissue and showed a stem-like immunophenotype, characterized by the ability to differentiate towards osteo-, chondro- and adipogenic lineages. The expression of markers referred to CAFs (alfa-SMA, HI-1alfa, MMP11, VEGF, CXCL12, TGF-Beta1, TGF-BetaRII, IL6, TNFalfa) was significantly higher in T-MSCs than in C-MSCs. The co-cultures with A549 cells led to the over-expression of selected oncogenes and to the increase of IL6 secretion in T-MSCs but not in C-MSCs. Conclusions: MSCs isolated from tumor tissue displayed distinct properties compared to MSCs isolated from healthy tissue, suggesting T-MSCs differentiation towards a CAF-related phenotype under the influence of the tumoral microenvironment

No disponible
Descriptores: neoplasias pulmonares/patología
células del estroma mesenquimatoso/patología
células madre neoplásicas/patología
fibroblastos asociados al cáncer/patología
-neovascularización patológica/patología
inductores de la angiogénesis/análisis
metástasis neoplásica/patología
carcinoma/patología
Límites: humanos
Responsable: BNCS


  8 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173764
Autor: Sabater, S; Montero, A; López Fernández, T; González Ferrer, JJ; Arenas, M.
Título: Management of patients with implanted cardiac devices during radiotherapy: results of a Spanish survey in radiation oncology departments
Fuente: Clin. transl. oncol. (Print);20(12):1577-1581, dic. 2018. tab.
Idioma: en.
doi: 10.1007/s12094-018-1893-5.
Resumen: Background: There is an increasing number of patients with cardiac implantable electronic devices (CIED), either pacemakers or defibrillators, who are receiving a course of radiotherapy. Several guidelines have been published by national societies, but no Spanish national guidelines for management of these patients have been published. More importantly, national clinical practice regarding these patients is not standardised. Materials and methods: Members of the Spanish Breast Cancer Radiation Oncology Group (GEORM in Spanish) were surveyed through an online questionnaire on behalf of the Spanish radiation oncology departments. Results: Only 39.3% of the Spanish radiation oncology departments have policies aimed at CIED carrier patients. Regardless of that, 96.4% of those who responded to the survey refer these patients to their Cardiology department before the start of the course of radiotherapy, and 17.8% of respondents said to manipulate the CIED without any cardiology department direction. A wide range of responses was obtained related to concepts such as ôdistance from the irradiation field to the CIEDö or ôsafe accumulated dosesö. Conclusions: Our results demonstrate the need for national guidelines for CIED patients and the need to promote educational activities addressed to standardise clinical management of these patients in the radiation oncology departments

No disponible
Descriptores: dispositivos de asistencia cardíaca/utilización
radioterapia/métodos
oncología radioterápica/métodos
neoplasias/radioterapia
-encuestas sobre atención a la salud/estadística & datos numéricos
desfibriladores implantables/utilización
marcapasos artificial/utilización
Límites: humanos
Responsable: BNCS


  9 / 2057 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 173763
Autor: Cacho-Diaz, B; San-Juan, D; Salmeron, K; Boyzo, C; Lorenzana-Mendoza, N.
Título: Choice of antiepileptic drugs affects the outcome in cancer patients with seizures
Fuente: Clin. transl. oncol. (Print);20(12):1571-1576, dic. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1892-6.
Resumen: Background: Seizures in cancer patients may occur as a result of CNS primary or metastatic tumor, brain surgery, vascular disease, pharmacologic treatment (including chemotherapy), radiation therapy, or metabolic disorders. The aims of the study were to a) determine whether seizures in cancer patients have prognostic implications and b) study patient outcome based on the antiepileptic drug used. Method: This is a prospective comparative study that included adult cancer patients with and without seizures from May 2010 to November 2016 seen by the neuro-oncology unit at a cancer referral center. Variables included age, gender, oncologic characteristics, seizure features, treatment, and outcome. Parametric and non-parametric tests were used to compare groups, and KaplanûMeier curves with the log-rank test were used to analyze survival. Cox multivariate regression tests were used to describe survival and compare groups. Results: A total of 823 patients were included; 419 (51%) patients had at least one seizure and were compared with 404 (49%) who did not experience seizures. Of the seizure group, 53% had brain metastases, 36% did not have a brain tumor, and 11% had a primary brain tumor. No survival differences were noted among patients with brain metastases or primary tumor with or without seizures. In the seizure group, 249 (59%) required only one antiepileptic drug, whereas 134 (32%) required 2 or more. A better overall survival was identified for patients prescribed carbamazepine (p = 0.02), lamotrigine (p = 0.015), levetiracetam (p = 0.03), and valproic acid (p = 0.009). Conclusions: Patients with primary or metastatic brain tumors have the same overall survival with or without seizures. However, patients with seizures not treated with antiepileptics exhibit worse overall survival

No disponible
Descriptores: convulsiones/tratamiento farmacológico
anticonvulsivantes/uso terapéutico
neoplasias cerebrales/complicaciones
-estudios prospectivos
resultado del tratamiento
tasa de supervivencia
neoplasias cerebrales/tratamiento farmacológico
Límites: humanos
Tipo de Publicación: estudio comparativo
Responsable: BNCS


  10 / 2057 IBECS  
              first record previous record
selecciona
para imprimir
Texto Completo
Id: 173762
Autor: Bellaye, PS; Moreau, M; Raguin, O; Oudot, A; Bernhard, C; Vrigneaud, JM; Dumont, L; Vandroux, D; Denat, F; Cochet, A; Brunotte, F; Collin, B.
Título: Radiolabeled F(ab')2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models
Fuente: Clin. transl. oncol. (Print);20(12):1557-1570, dic. 2018. ilus, graf.
Idioma: en.
doi: 10.1007/s12094-018-1886-4.
Resumen: Purpose: This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, 111In and 177Lu, respectively. Methods: We designed F(ab′)2-fragments of cetuximab radiolabeled with 111In and 177Lu. 111In-F(ab′)2-cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors. The efficacy of 111In-F(ab′)2-cetuximab to assess therapy efficacy was performed on BalbC nude mice bearing colorectal tumors receiving 17-DMAG, an HSP90 inhibitor. Therapeutic efficacy of the radioimmunotherapy based on 177Lu-F(ab′)2-cetuximab was evaluated in SWISS nude mice bearing A431 tumors. Results: Radiolabeling procedure did not change F(ab′)2-cetuximab and cetuximab immunoreactivity nor affinity for HER1 in vitro. 111In-DOTAGA-F(ab′)2-cetuximab exhibited a peak tumor uptake at 24 h post-injection and showed a high tumor specificity determined by a significant decrease in tumor uptake after the addition of an excess of unlabeled-DOTAGA-F(ab′)2-cetuximab. SPECT imaging of 111In-DOTAGA-F(ab′)2-cetuximab allowed an accurate evaluation of tumor growth and successfully predicted the decrease in tumor growth induced by 17-DMAG. Finally, 177Lu-DOTAGA-F(ab′)2-cetuximab radioimmunotherapy showed a significant reduction of tumor growth at 4 and 8 MBq doses. Conclusions: 111In-DOTAGA-F(ab′)2-cetuximab is a reliable and stable tool for specific in vivo tumor targeting and is suitable for therapy efficacy assessment. 177Lu-DOTAGA-F(ab′)2-cetuximab is an interesting theranostic tool allowing therapy and imaging

No disponible
Descriptores: nanomedicina tratanóstica/métodos
cetuximab/uso terapéutico
neoplasias colorrectales/diagnóstico por imagen
neoplasias cutáneas/diagnóstico por imagen
radioinmunoterapia/métodos
-modelos de enfermedad en animales
neoplasias colorrectales/terapia
neoplasias cutáneas/terapia
marcado isotópico/métodos
genes erbB-1/efectos de radiación
Límites: animales
ratas
Responsable: BNCS



página 1 de 206 va a la página                         
   


Refinar la búsqueda
  Base de datos : IBECS Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud